Unlocking the therapeutic power of personalized genetic medicine

Screen Shot 2017-08-28 at 7.18.20 PM.png

Our Company

Mediphage Bioceuticals is a genetic medicine company focused on developing safe, effective, and accessible gene delivery platforms to unlock the therapeutic power of personalized, redoseable, genetic medicine.


December, 2015

Mediphage Bioceuticals was formed as a spin off company from the University of Waterloo in Ontario, Canada.

Seed Round.

March, 2016

Mediphage Bioceuticals closes its seed round to develop proof of concept and perform early stage efficacy studies.

Proof of Concept.

February, 2017

Mediphage Bioceuticals successfully develops its DNA Ministring production and targeting technology. Mediphage also completes early stage proof of concept efficacy studies.

JLABS @ MaRS Toronto.

March, 2017

Mediphage Bioceuticals moves to JLABS at the MaRS Discovery District. Mediphage enters late stage safety and efficacy studies and executes feasibilty studies with key biopharma partners.

Illumina Accelerator.

April, 2018

Mediphage Bioceuticals moves to San Francisco for the Illumina Accelerator program, carrying out key genomics projects and initiating Mediphage's next round of funding.

Commercial Manufacturing.

December, 2018

Mediphage Bioceuticals implements large-scale, high speed msDNA manufacturing to support growing biopharma partnerships and internal therapeutic development efforts.



Screen Shot 2017-08-28 at 8.52.21 PM.png

Our Technology


DNA Ministrings


Our flagship technology, ministring DNA (msDNA), is a safe, effective and highly accessible nonviral gene delivery vector for the redoseable delivery of genes into cells for gene therapy, cell engineering and gene editing. Unlike conventional viral and nonviral gene delivery systems, msDNA has a linear covalently closed “string” topology, making it the safest tool for gene delivery without compromising effectiveness, and can be produced at a fraction of the cost of competing solutions.

Here’s how we compare:

  • Highly scalable and efficient production: Mediphage Bioceuticals’ patented E.coli “in vivo” production system allows for the rapid production of large scale quantities of msDNA, while being highly cost-effective.

  • Safer composition and design: msDNA is the only vector capable of protecting individuals from harmful mutations by selectively inducing cell death upon undesired chromosomal integration.

  • Redoseable and personalized gene therapy: msDNA contains no immunostimulatory components, which enhances safety and allows for redoseable administration.

  • Large vector capacity: msDNA has a substantially large vector capacity, and can be used to treat monogenic disorders for which therapeutic genes exceed traditional vector capacity.

With the highest safety profile across viral and nonviral transgene delivery vectors, msDNA enhances the transition of current genetic engineering technology into true personalized genetic medicine.


Current Applications of msDNA

Ministring DNA is an efficient, customizable and redosable vector for ex vivo and in vivo cell or gene therapies, and lymphocyte (B-cell and T-cell), stem cell and gene editing therapeutics. Our msDNA technology is currently being evaluated by therapeutic development partners using gene therapy, chimeric antigen receptor T-cells, DNA vaccines, induced pluripotent stem cells, CRISPR and B-cell immunotherapy approaches, as well as recombinant adeno-associated viral production, across a variety of applications.


Our Team


Moses Cesario,


  • 18 years experience leading life science companies

  • formerly CEO of Previvo Genetics, COO of Neomorphic Software (bioinformatics), and VP and CIO of Affymetrix, Inc. (microarray technology and genomics analysis)

moses cesario headshot circle 350x353.png

Dr. Roderick Slavcev,

Founder & CSO, Executive Director, 
HBSc, PhD, MBA, MRSB, C.Biol

  • Associate Professor, Pharmaceutical Sciences

  • Professor, Business & Entrepreneurship School of Pharmacy, University of Waterloo

  • Chartered Biologist, Royal Society of Biology

roderick slavcev 350x350.png

Lee Bowman,

Chief Operating Officer

  • MA - International Relations

  • BMath - Computer Science (Bioinformatics)

Lee Bowman Headshot 350x350.png

Nafiseh Nafissi

Director of R&D, PhD, MSc

  • B.W. Pearson Research Medal (2014)

  • University of Waterloo School of Pharmacy Award of Excellence (2013)

Nafiseh headshot transparent 350x350.png

Advisory Board

sanjay singh headshot 210x280.png

Dr. Sanjay Singh, President & CEO, Temple Therapeutics B.V. Director, BioteCanada

Todd Meyerrose headshot 210x280.jpeg

Dr. Todd Meyerrose,
Founder & CEO, Path Drugomics

jake thiessen headshot 210x280.jpg

Dr. Jake Thiessen, Associate Dean and Founder, University of Waterloo, School of Pharmacy (retired)

Our Support

Illumina Accelerator_color.png
University of Waterloo.png